BIOPHARMA
By
How Did Johnson & Johnson Navigate 2025 and What Lies Ahead for 2026?
Johnson & Johnson concluded 2025 with a combination of resilient portfolio performance, strategic execution, and ongoing innovation across…
How Did Novartis’ 2025 Deals Shape Its Strategic Direction and What Might They Signal for 2026?
Novartis’ deal activity in 2025 reflected a deliberate and strategic effort to strengthen its scientific platforms, broaden its…
How Did Novartis Navigate 2025 and What’s Ahead for 2026?
In 2025, Novartis demonstrated resilience and strategic focus, balancing strong performance in its core franchises with investments in…
How Did AbbVie’s 2025 Deals Shape Its Year, and What Do They Signal for Growth in 2026?
NORTH CHICAGO, IL — As 2025 concludes, AbbVie Inc. reflects on a year of strategic dealmaking that complements…
Can Johnson & Johnson’s 2025 Product Momentum and Portfolio Execution Sustain Leadership Across Oncology, Immunology, and MedTech Into 2026 and Beyond?
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one of the world’s…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce Leadership in HIV, Oncology, and Liver Disease Into 2026 and Beyond?
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025 through a focused…
